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Abstract
Islet transplantation is currently the only minimally invasive therapy available for 
patients with type 1 diabetes that can lead to insulin independence; however, it is 
limited to only a small number of patients. Although clinical procedures have improved 
in the isolation and culture of islets, a large number of islets are still lost in the pre-
transplant period, limiting the success of this treatment. Moreover, current practice 
includes islets being prepared at specialized centers, which are sometimes remote to 
the transplant location. Thus, a critical point of intervention to maintain the quality 
and quantity of isolated islets is during transportation between isolation centers and 
the transplanting hospitals, during which 20–40% of functional islets can be lost. The 
current study investigated the use of an oxygen-permeable PDMS microwell device 
for long-distance transportation of isolated islets. We demonstrate that the microwell 
device protected islets from aggregation during transport, maintaining viability and 
average islet size during shipping.
Introduction
Diabetes mellitus affects about 390 million people 
worldwide, with a steady increase in global incidence over 
the last decades (1, 2). Of these, an estimated 7–12% are 
diagnosed with type 1 diabetes (T1D) (3). T1D patients 
are required to measure blood glucose levels and inject 
insulin multiple times per day and often experience severe 
impairment of quality of life and potential long-term 
effects such as microvascular complications and organ 
damage (4, 5, 6, 7, 8). Currently, there is no prevention 
or cure for T1D, and the only minimally invasive 
therapy available that can lead to insulin independence 
is islet transplantation. Since the publication of an 
improved protocol for islet isolation and transplantation 
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transplants have been performed globally (11). However, 
the procedure is currently limited to a small group of 
T1D patients with brittle diabetes or hypoglycemia 
unawareness (unawareness of critically low blood glucose 
levels) (12). The major reason for the limited availability of 
this therapy is one of supply: the dearth of suitable donor 
pancreata and the loss of functional insulin-producing 
islet tissue throughout the isolation and transplantation 
process (13, 14).
The process of isolating islets from the pancreas of 
a deceased organ donor follows a complex protocol that 
is both labor and time-intensive. This process requires 
expensive isolation facilities equipped with clean-room 
facilities operating to Good Manufacturing Practice 
(GMP) standards and staffed with a team of experienced 
professionals able to perform the isolation (15, 16). 
Therefore, to ensure the quality of the islet isolation 
process and to reduce the total costs associated with islet 
transplantation, it is advantageous to have centralized 
isolation facilities from where isolated islets are shipped 
to different clinical transplantation centers. This hub and 
spoke model approach requires the transport of islet tissue, 
often across long distances, while maintaining the quality 
and quantity of islets. Clinical islet transplant networks 
such as in the United Kingdom, the Swiss-French Gragil 
consortium, the Nordic network and Australia all use this 
this model for their clinical islet transplant programs (17).
The minimum transplant requirement is ≥5000 islet 
equivalents (IEQ) per kg body weight of the recipient (9). 
Many islet preparations fulfill this criterion after isolation, 
but the functional islet mass often decreases below this 
threshold during culture and transport. Currently, it is 
estimated that 20–40% of functional insulin-producing 
islet tissue can be lost during the peri-transplant phase, 
where islets are cultured, quality tested and shipped 
to the transplant center (18, 19). It has been shown in 
several studies that islet transport and associated stress 
conditions such as high tissue density, mechanical force 
and oxygen deprivation can lead to islet damage and 
cell death, impacting on the functional islet mass for 
transplantation.
Improvement of islet survival during transport 
is therefore a critical step to increase the number of 
successful transplantations and to reduce the number 
of isolations required to enable each clinical transplant. 
Such an achievement would open this treatment to more 
patients and reduce the overall cost of the transplant 
procedure. An improved islet transport device could 
also be widely applied to emerging beta-cell replacement 
technologies, such as insulin-secreting tissues from adult 
and embryonic stem cells and islets from animal sources, 
which aim to alleviate organ shortage barriers.
Currently, cell culture bags made of gas permeable 
polymers such as poly(tetrafluoroethylene), 
poly(tetrafluoroethylene)co-(hexafluoropropylene) or 
silicone rubber membrane are employed for islet transport 
(20, 21). Freshly isolated islets are dispersed in a transport 
medium and loaded into the bags prior to transport to 
the transplantation centers (22). Conventional transport 
containers such as culture bags or flasks do not segregate 
or immobilize the islets; consequently, islets can freely 
move and interact with each other during transport. Such 
interactions induce aggregation and shear-fragmentation 
of the islets, thereby changing the shape, size and viability 
of the clusters. Larger islet aggregates have been shown to 
have a hypoxic core, potentially leading to the impairment 
of islet function and viability (23, 24, 25). Therefore, a 
transport device that will reduce islet aggregation and 
fragmentation is expected to improve the cell survival 
during shipping.
In this study, we report the development of a 
novel transport format that compartments islets on a 
poly(dimethylsiloxane) (PDMS) microwell array to reduce 
islet interactions. PDMS is an oxygen-permeable silicon 
rubber, allowing the high oxygen requirements of human 
islets to be supported (26). We show that the microwell 
device protected islets from aggregation during transport, 
maintaining viability and average islet size during 
shipping, whereas islets shipped under standard control 
conditions showed a loss in viability and average islet size.
Methods and materials
Microwell fabrication and characterization
Fabrication
The design of the microwell devices was created in 
Solidworks (Dassault Systems, France), a computer-
aided drawing (CAD) software, then exported as a 
.STEP file for 3D printing of the casting molds. Casting 
molds were fabricated for a two-part device: a base, 
containing the microwell structures, and a lid used to 
enclose pancreatic islets during shipping studies. The 
molds were printed from temperature resistant HED525 
plastic using a PolyJet printer (Objective 3D, Australia). 
Upon receipt, each part was thoroughly washed with 
deionized water and allowed to dry, then coated by 
plasma polymerization using the fluorosurfactant Zonyl 
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(Sigma-Aldrich) (Supplementary Fig.  1, see section on 
supplementary data given at the end of this article). 
Plasma deposition was performed in a purpose-built 
capacitively coupled bell-chamber reactor (27, 28, 29). 
The cleaned 3D printed parts were added to the plasma 
reactor and the chamber brought to a vacuum. To further 
clean and prime the 3D printed parts, atmospheric air 
was introduced into the chamber until a steady pressure 
of 1.1/10 mbar was achieved. A plasma was ignited in 
air with a 50 W continuous wave (CW) radio frequency 
(RF) for 5 min. This process ensured that any unwanted 
organic material on the surface was removed prior to 
polymer deposition and activation. Subsequently, the 
pressure in the chamber was lowered to 100 mTorr 
and the Zonyl monomer was introduced via a needle 
valve until steady working flow rates were achieved. 
The plasma was ignited with a 20 W CW RF for 4 min. 
The Zonyl plasma polymer formed a non-adhesive layer 
on the mold surface, facilitating removal of the cast 
PDMS device. The plasma reactor and precise procedure 
have been previously reported (27, 28, 29). Because 
plasma polymer coating is substrate independent, a 
piece of silicon wafer was introduced into the chamber 
for each coating run facilitated, to enable subsequent 
characterization of the plasma coating using contact 
angle and ellipsometry. After plasma polymer coating, 
the device parts were left overnight at room temperature 
to allow the coating to settle. For PDMS casting of the 
device, Sylgard 184 (Corning) was mixed according to 
the supplier’s specification, and degassed under vacuum 
until a clear liquid was obtained. The Sylgard solution 
was then poured onto the coated molds and cured at 
60°C overnight. The cured parts were removed from the 
mold and sonicated in acetone and ethanol for 20 min 
in each solvent. Finally, the parts were cured for 1 h 
at 100°C. A nylon mesh (Clear Edge Filtration, Tulsa, 
OK, USA) with a pore size of 50 µm used as the holding 
membrane was cut to size with a compass cuter. Prior 
to use, the parts were washed with 70°C ethanol and 
gamma irradiated (30 Gy) to ensure sterility.
Ellipsometry
Clean silicon wafers were exposed to the same plasma 
polymerization treatment as the 3D-printed mold parts 
and were used for further characterization of the plasma 
polymer coating. Coating thickness on the silicon wafers 
was determined via ellipsometry using a J. A. Woolam 
Co. (Lincoln, Nebraska, USA) variable angle spectroscopic 
ellipsometer (VASE). All measurements and data were 
analyzed using WVASE32 software provided with the 
instrument. Polymer thickness values were estimated by 
applying a Cauchy model (Supplementary Table 1).
Contact angle
A custom-built sessile drop apparatus with an Olympus 
SZ-PT microscope and lens system mated to a Sony CCD 
camera was employed to measure the wettability of 
the plasma-coated surfaces. A 10 µL syringe (Hamilton, 
Reno, USA) was used to dispense droplets of MilliQ water 
of approximately 1 µL on the blank or Zonyl plasma-
coated silicon wafer. A minimum of three contact 
angle measurements were taken from each surface. 
Angle analysis of captured droplets was performed with 
ImageJ software, v1.50 with the DropSnake plugin 
(Supplementary Table 1).
Scanning electronic microscopy (SEM)
SEM images were obtained using a field emission SEM 
(Merlin, Zeiss, Germany), fitted with a GEMENI II column 
(Zeiss, Germany) and a secondary electron detector, 
operating at 1 kV in high vacuum mode. Measurements 
of microwell dimension were performed using the open 
source software ImageJ 1.50.
Islet isolation and culture
Murine islets
Mouse islets of Langerhans were isolated from 6- to 
12-week-old male or female C57Bl/6 mice using 
collagenase P (Roche) and Histopaque-1077 density 
gradients (Sigma-Aldrich) as previously described (30, 31). 
Islets were cultured at 37°C and 5% CO2 in RPMI (Sigma) 
or CMRL (Gibco-Invitrogen) supplemented with 2 mM 
l-glutamine, 100 U/mL penicillin, 100 U/mL streptomycin 
and 10% fetal calf serum. All animal experiments were 
approved by independent animal ethics committees of 
the University of Adelaide, SA Pathology and St Vincent’s 
Hospital, Melbourne.
Human islets
Human pancreata were obtained, with informed consent 
from next of kin, from heart-beating, brain-dead donors, 
with research approval from HREC committee at the 
St Vincent’s Hospital Melbourne. Human islets were 
purified by intraductal perfusion and digestion of the 
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pancreas with collagenase followed by purification using 
Ficoll density gradients (32). Purified islets were cultured 
in Connaught Medical Research Laboratories (CMRL) 
1066 medium (Invitrogen) supplemented with 10% 
human serum albumin, 100 U/mL penicillin, 100 mg/mL 
streptomycin and 2 mM l-glutamine (complete CMRL), in 
a 37°C, 5% CO2 humidified incubator.
Shipping protocol and handling
After isolation, mouse islets were cultured on the PDMS 
microwell device in complete CMRL medium overnight at 
37°C, 21% O2, 5% CO2. Control cultures, using standard 
non-adherent tissue culture plastic, were performed in 
parallel. The next morning, control islets were transferred 
into a 1.7 mL screw-cap microfuge tube. Tubes were filled 
with complete media before sealing. This is representative 
of shipping human islets in 50 mL Falcon tubes, a practice 
that is widely used in many isolating centers worldwide 
and an accepted reference shipping method (22, 33, 34). 
The PDMS devices were prepared for transport by inserting 
a permeable filter mesh to cover the islet-containing 
microwell surface, then filling the device with complete 
media before closing and sealing the device with the cast 
PDMS lid (Fig.  2). As shown in Supplementary Fig.  2A, 
the microwell device and microtube control were loaded 
into a stabilizing wire rack, which was then placed into a 
zip-lock plastic bag, closed to trap as much air as possible 
in the bag. This bag was then placed into a styrofoam 
box containing cold packs to stabilize temperature during 
shipment. Temperature fluctuation was monitored during 
shipping by a temperature probe (Supplementary Fig. 2B). 
Complete packages were shipped via a commercial courier 
service, involving road transport from the isolating center 
to the local airport and then a commercial flight to the 
destination city (730 km) and then road transport to 
the receiving center. These conditions exactly replicate 
our clinical islet transplant program (35). Upon arrival 
after transport or at the end of the pseudo-shipping 
period, the microwell device was transferred to a cell 
culture incubator at standard conditions (37°C, 21% O2, 
5% CO2). Islets transported in the control device were 
transferred to a suspension 6-well plate and incubated in 
the same way overnight. For pseudo-shipping, conditions 
were simulated by 5–6 h on moving platform at a speed 
of approximately 60 rpm (denoted as pseudo-shipping 
conditions). To recover islets from shipping device, the 
mesh was removed and then gentle pipetting was used 
to allow islets to become suspended and collected. A final 
PBS wash of the wells ensured maximal collection.
Islet size determination
After 24-h post-shipping islets were collected and bright-
field images of the islets were obtained at 40× magnification 
(Nikon Eclipse Ti-U Microscope, DS-Qi2, Nikon). Using 
NIS-Elements BR Microsoft image software (Nikon), 100 
islets were randomly selected from these images and 
measured. An average size for each shipped preparation 
was then calculated and used for further analysis.
Human islet density and loading analysis
To quantify the efficiency of device loading, human islets 
were cultured on the microwells of different microwell 
size (300, 500 and 700 μm) and exposed to pseudo-
shipping conditions (5–6 h on moving platform at a 
speed of approximately 60 rpm) at room temperature. The 
microwell devices were imaged before pseudo-shipping 
(pre-shipping) and after pseudo-shipping (post-shipping) 
on an upright microscope (Olympus CKX41). The 
number of islets per microwell was manually counted for 
each microwell array design over six fields of views and 
the distribution of islet content per microwell was then 
calculated. For the other assays, the islets were removed 
from the shipping devices to carry out the assays according 
to state-of-the-art protocols.
FDA/PI viability assay
Mouse islet samples were stained to determine whole islet 
viability with fluorescein diacetate (FDA, Sigma-Aldrich) 
and propidium iodide (PI, Sigma-Aldrich). In brief, 
islets were transferred to a 24-well suspension plate in 
400 µL volume, PI and FDA were added to achieve a final 
concentration of 5 µg/mL and 5 µM, respectively. Samples 
were incubated at room temperature for 5–10 min and 
imaged as soon as possible. Fluorescent images were taken 
using the Nikon Eclipse Ti-U Microscope (DS-Qi2) (Nikon) 
and the NIS-Elements BR Microsoft image software 
(Nikon) was used for image analysis.
Oxygen consumption rate
Oxygen consumption rate (OCR) was determined using 
a commercially available Micro Oxygen Uptake System 
(Instech Laboratories, Plymouth Meeting, PA, USA), 
a method described in detail by Papas and colleagues 
(36). Briefly, OCR of murine islets was determined 
from the linear decrease of pO2 over time, which was 
then normalized to DNA content of the islets in each 
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sample using the Quant-iT PicoGreen dsDNA Assay 
kit as per manufacturer’s instructions (Invitrogen, Life 
Technologies).
Quantitative real-time PCR
Extraction and purification of RNA was performed using 
RNAqueous Micro Kit (Ambion cat no AM1931) according 
to the manufacturer’s instructions. The purified RNA was 
quantified by absorbance at 260 nm using a NanoDrop 
2000. RNA (200–500 µg) was reverse transcribed in a 20 µL 
reaction using iScript Reverse Transcription Supermix 
for RT-qPCR (Biorad Cat no. 1708841) according to the 
manufacturer’s instructions. The complete reaction 
mix was diluted 1:2 following an incubation of 5 min 
at 25°C, 30 min at 42°C and 5 min at 85°C. Real-time 
quantitative PCR analysis was performed on duplicate or 
triplicate samples, using 2 µL of cDNA using the following 
gene-specific TaqMan primers (Applied Biosystems; 
Life Technologies): Mcp-1 (Ccl2 (Mm00441242_m1)), 
Glut-2 (Slc2a2 (Mm01333430_m1; Mm00446229_m1)), 
Ldha (Mm1612132_g1), Il6 (Mm00446190_m1), Pdx1 
(Mm00435565_m1) and Insulin (Mm01950294_s1). B-actin 
(ACTB Mm02619580_g1) was used as a housekeeping 
gene and to normalize expression data using 2−Δct as a 
method of quantitation.
Statistical analysis
Data were analyzed using Prism 6 (Graph pad). Results are 
expressed as mean ± S.E.M. or ±S.d. as indicated by individual 
figures legends. A value of P < 0.05 was considered 
statistically significant and all P values reported were 
two-sided, unpaired Student’s t-test or as indicated in the 
figure legend.
Results and discussion
Most published microwell arrays have been made from 
polymeric materials, including collagen (37), agarose 
(38, 39), poly(ethylene glycol) (PEG) (40), poly(butylene 
terephthalate)-co-(ethylene oxide terephthalate) 
(PEOT/PBT) (41) or PDMS (39, 42). While the 
biocompatibility of these materials is comparable, 
PDMS allows greater oxygen diffusion and the platform 
Figure 1
3-D rendering of the computer-aided drawings of (A) the microwell mold and (B) the lid mold. Photograph of (C) the 3-D printed microwell mold and 
(D) the lid mold. Polydimethylsiloxane (PDMS) (E) casted microwell inserts and (F) lids closing the device base, the arrow shows the side opening for 
complete loading of the device. The PDMS molds fit into 6-well plate format, modified with opening at the top and bottom to allow gas exchange.  
(G) Photograph of the loaded PDMS microwell device. (H) Representative photograph of islets within the microwells.
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described here could be further developed to incorporate 
oxygen releasing coating as previously reported for PDMS 
(43). Thus, PDMS was the material of choice in this study 
due to its high oxygen permeability and facile fabrication 
(39, 44). With CAD software, we designed a mold for a 
two-part container with a base and a lid (Fig. 1A and B). To 
allow for incorporation within conventional laboratory 
tissue culture plastic, the container can be fitted into a 
6-well plate. The microwells were imprinted in the base 
of the device. The device lid was constructed to hold a 
semi-permeable membrane in close contact with the 
imprinted base, in order to restrict movement of the islets 
from one well to another during shipping but allowing for 
exchange of nutrients and oxygen, offering a considerable 
advantage compare to current transport protocols where 
islets can freely move in a culture bag or a flask. The molds 
were 3D-printed from urethane-acrylate, a heat-resistant 
material, to be compatible with PDMS curing at 60°C 
(Fig.  1C and D). However, after curing, PDMS became 
adherent to the 3D printed mold. Therefore, the mold was 
coated with a fluorinated plasma polymer using perfluoro-
1-hexene (Zonyl) as monomer. This coating facilitated the 
release of the PDMS parts out of the mold. This technique 
allowed us to quickly obtain the PDMS parts utilized for 
the transport device: bottom microwells and lid (Fig. 1E 
and F). The transport device could then be loaded with 
the islet suspension and closed with the lid (Fig. 1G and 
H). Because the PDMS is a polymer network, the microwell 
base and the lid formed a watertight seal on contact.
Subsequently, we developed a protocol for the efficient 
loading of the transport device with islets (Fig.  2). The 
PDMS microwells were loaded with an islet suspension 
and the islets were allowed to settle into the microwells 
overnight. The islets do not adhere to the PDMS; thus, 
the islets can freely move out of the microwells. To limit 
movement of the islets out of the microwells, a semi-
permeable membrane with a 50 µm mesh was positioned 
on top of the microwells. The device was loaded with cell 
culture media and the lid was placed inside the device. 
By tilting the device, the device could be completely 
filled with culture media, and air evacuated. When fully 
inserted, the lid not only closed the device but also held 
the membrane in position on top of the microwells. 
This last manipulation was critical, as the presence of 
an air bubble can expose the islets to air and limit access 
to nutrients if the device is tilted during the transport. 
Successful loading of the islets in the microwell device 
was assessed by observation using an upright microscope 
(Fig. 1G and H).
Given the clear consensus that anoxic conditions are 
detrimental to the overall health and function of islets 
(24), gas permeable bags are often employed for islet 
culture and transportation pre-transplant (22). However, 
islets transported in semi-permeable bags showed 
significant loss of islet integrity, despite having comparable 
viability to a non-permeable blood transfusion bag. It was 
postulated that the shear stress from the bag movement 
during transport leads to the change in islet integrity (45). 
Moreover, these bags are difficult to handle, promote the 
aggregation of islets and have a propensity to rupture and 
become contaminated.
To avoid islet aggregation and fragmentation, we 
created a closed device housing an array of microwells, 
sized to spatially isolate islets during transport. Implantable 
microwell scaffold arrays have previously been reported 
Figure 2
3-D rendering of the computer-aided drawings representing the islet 
loading process within the microwell array. (A) The islet suspension was 
loaded on a microwell array that is then incubated for 24 h at 37°C, (B) 
then a 50 µm membrane was deposited on top of the microwells and (C) 
extra transport medium was added to top up as much as possible. (D) 
Then, the lid was placed on the top of the microwell array leaving the 
side opening free to allow for media top up. (E) Finally, the lid was gently 
closed forming a watertight seal and the device was placed with a 6-well 
plate, ready for shipping.
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to improve cell survival for extrahepatic implantation of 
islets (41). In addition to being tested as an implantable 
platform, such microwell arrays have also been extensively 
used in the formation of β-cell aggregates from dissociated 
pancreatic islets (40, 46, 47) or from the insulin-producing 
MIN6 cell line (48, 49, 50). These microwell platforms, 
however, were fabricated using expensive manufacturing 
techniques such as soft lithography or hot embossing, 
which do not allow for rapid prototype generation. Here, 
we generated a prototype microwell shipping device 
using inexpensive techniques with a tunable microwell 
diameter.
Theoretically, optimal islet segregation during 
transport is achieved when each microwell houses a 
single islet. However, due to the size distribution of 
human islets, ranging from 50 µm to over 350 µm (51) 
and in some instances up to 600 µm, it was expected 
that microwells may harbor several islets. In order to 
determine the optimal microwell diameter configuration 
– minimizing clustering of small islets while being large 
enough to accommodate larger islets – we designed three 
different microwell array designs with well diameters of 
300, 500 and 700 µm (Fig. 3A, B and C). The microwell 
cross-section was imaged by SEM to verify the successful 
imprinting of the mold (Fig. 3D, E and F). In each case, the 
depth of the microwells was identical: 500 µm.
Human islets were used to assess islet loading and 
distribution over the different microwell sizes under 
simulated shipping conditions. As described in detail 
in the Materials and Methods section, the number of 
islets contained per well was counted for each microwell 
size, pre-simulated and post-simulated shipping (Fig.  4 
and Supplementary Table 2). For the smallest microwell 
diameter assessed (300 µm), few islets entered the 
microwells upon loading, and these were not retained 
within the microwells during pseudo-shipping. The 
majority of islets aggregated on the surface of the device 
and did not enter the microwells. In contrast, microwells of 
700 µm diameter housed multiple islets per well (around 4 
islets per microwell on average) after loading and pseudo-
shipping. The capacity of the 500 µm diameter microwells 
was sufficient to load islets efficiently, while segregating 
islets into individual wells (1.4 and 1.8 islets per microwell 
before and after simulated shipping, respectively, 
(Supplementary Table 2). As the 500 µm microwell format 
produced optimal human islet loading and segregation, 
we chose this format for further investigations of islet 
viability and function.
To provide standardized islet tissue for assessment of 
the shipping device, we used islets from C57Bl/6 mice 
to assess the biological responses following shipment in 
our prototype device. Islet viability and function were 
compared after shipment of islets on the microwell 
devices and under standard reference conditions in non-
gas-permeable tubes (22, 33, 34). We determined islet 
viability of murine islets subjected to pseudo-shipping 
for 5 h, a time period that reflects the transportation 
time of islets between isolation and transplanting centers 
using commercial carriers based on our experience 
(Supplementary Table  3) and others (52). Islets were 
collected and analyzed directly after pseudo-shipping 
and also after 24-h culture post pseudo-shipping. 
As shown in Fig.  5, assessment of islet viability with 
FDA/PI did not reveal a significant difference between 
islets from the control tube (Fig. 5A, B and C) and islets 
from the microwell device (Fig.  3D, E and F). Despite 
Figure 3
3-D rendering of the CAD of the mold used to 
make the microwells array of different sizes with 
microwells sizes of 300, 500 and 700 µm (A, B and 
C). Scanning electron microscope (SEM) 
micrographs of the microwell cross-section (D, E 
and F) 300, 500 and 700 µm, respectively. Scale bar 
250 µm.
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being an accepted viability test for clinical preparations, 
detection of subtle viability changes using FDA/PI has 
been a common challenge in the field of islet biology 
(53, 54). It has been shown that the OCR of islets can 
reveal variability in preparations that otherwise cannot be 
separated by FDA/PI (55). This method has recently been 
proposed as a predictive marker to determine islet quality 
prior to transplantation (56, 57). For this reason, we also 
used OCR/DNA ratio as a measure of metabolic rate and 
a surrogate marker of islet viability. No difference was 
observed in the OCR of islets 24 h after pseudo-shipping 
(Fig.  5G), suggesting a similar oxygen metabolic rate in 
islets from both the device and control tubes following 
simulated transport.
We performed size analysis of 100 randomly 
selected islets per image of islets from three independent 
experiments after pseudo-shipping in the microwell device 
and control tubes. As shown in Fig. 5H, islets shipped in 
microwell devices were significantly larger on average than 
islets from control tubes (P = 0.027). Given that for each 
experiment, islets shipped by each method originated 
from pooled starting populations of isolated murine islets, 
this indicates that islets from control tubes have a reduced 
islet mass. Islets shipped within the microwell device 
retained a similar size to islets that did not undergo islet 
shipping (indicated by the red-dash line, Fig. 5H). Bright-
field images of islets from microwell device (Fig. 5J) and 
control tube (Fig.  5I) revealed subtle differences in islet 
morphology. Islets incubated in control tubes exhibited 
ruffled edges compared to islets from microwell devices.
It has been shown that the transcriptional profile of 
human islets during isolation and culture reflects changes 
in viability and function in response to two major stress 
factors, inflammation and hypoxia (56, 58, 59, 60, 61). 
These transcriptional changes are conserved in model 
species (rat and mouse) (62, 63, 64). We analyzed validated 
markers of islet viability (Ldha, Slc2a2), inflammatory 
response (Ccl2, Il6) and islet differentiation/function 
(insulin (Ins), Pdx1) in murine islets subjected to pseudo-
shipping. Samples were collected directly at the end of 
the 5-h pseudo-shipping period, and again at 24 h post 
shipping. Islets cultured under standard culture conditions, 
exposed to hypoxia (2% O2, 5 h) or the cytotoxic cytokine 
TNF-alpha (5 h) were used as controls for induction or loss 
of target gene RNA expression, respectively. Expression of 
lactate dehydrogenase A (Ldha) is suppressed in mature 
beta-cells and associated with anaerobic metabolism 
(45, 58, 65). Islets pseudo-shipped in control tubes or 
microwell device showed no significant changes to Ldha 
transcription in relation to culture control after 5 h of 
pseudo-shipping (Fig. 6A).
However, after 24-h Ldha transcription levels 
significantly increased in islets from control tubes compared 
to the 24-h culture control and the islets shipped in the 
microwell device (P = 0.0218 and P = 0.0133 respectively). 
This level of Ldha transcription in islets from control tubes 
was comparable to the positive hypoxia control (P = 0.870). 
The expression of glucose transporter 2 (Slc2a2) an essential 
glucose-sensing molecule (66, 67) was also investigated. 
Directly after pseudo-shipping, there were no significant 
changes in Glut2 gene expression between the culture 
control and the test groups. However, Glut2 expression 
of islets shipped in the microwell device did significantly 
increase at 24 h when compared to the sample taken at 5 h. 
No significant changes were observed at 24 h between the 
groups (Fig. 6B). Expression of the cytokine Il6 (Fig. 6C) 
was transiently induced after shipping in microwells after 
Figure 4
Islet distribution within 300, 500 and 700 µm microwell arrays (A) before 
pseudo-shipping experiment and (B) after pseudo-shipping experiment. 
The microwell device is able to maintain islet size and hypoxia-related 
gene expression at basal levels during simulated shipping.
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5 h when compared to culture controls, but not the control 
tube. This slight rise in IL6 transcript levels then returned 
to basal levels after the 24-h culture period. Similarly, 
there was a slight rise in expression of the chemokine 
Mcp1 (Ccl2) in islets from control tubes (Fig. 6D) at 5 h, 
which then decreased at 24 h, though changes were not 
statistically significant. Analysis of the mRNA expression 
of insulin (Ins) (Fig. 6E) showed no significant changes in 
islets pseudo-shipped in control tubes compared to that 
on the microwell device. There was a slight but significant 
increase in insulin mRNA in the microwell-shipped islets 
when compared to culture control islets. However, this 
trend did not persist at 24 h, where the expression was 
similar in all groups. Islet differentiation transcription 
factor Pdx1 showed a small significant decrease at 24 h in 
microwell shipped islets when compared to the culture 
control. However, this was not statistically different to 
islets from the control tube (Fig. 6F).
Overall, our results indicated that the microwell 
device retained high viability in healthy mouse islets 
under simulated shipping conditions. Induction of stress 
responses was moderate and transient. We next tested the 
capacity of the microwell device to support islet integrity 
and survival under real shipping conditions, reflecting the 
process currently used for human islet transplantation.
To demonstrate the performance of the microwell 
device under real-world long-distance shipping conditions 
via air and road, we transported mouse islets in the 
Figure 5
Shipping of murine islets under pseudo-shipping 
conditions. Islets were subjected to pseudo-
shipping, and then cultured for 24 h and assessed 
for whole islet viability using fluorescent FDA and 
PI, for islets from the control tube (control) (A 
and B) and islet shipped in the microwell device 
(D and E), and overlays (C and F), representative 
of 3 independent experiments, 100× 
magnification. Mean OCR of islets subjected to 
pseudo-shipping in control tube or on microwell 
device is shown in (G) from 4 independent 
experiments +/− S.E.M. Mean area per islet was 
determined by randomly selecting 100 islets per 
preparation, data from three independent 
experiments is represented in graph (H), *P < 0.05, 
two-tailed T-test, error bars +/− S.E.M., where the 
red-dash line is representative of the average size 
of unshipped islets. Bright-field images of the 
islets after removal from microwell device (J) and 
control tube (I).
This work is licensed under a Creative Commons 
Attribution 4.0 International License.https://doi.org/10.1530/EC-17-0349
http://www.endocrineconnections.org © 2018 The authors
Published by Bioscientifica Ltd
Downloaded from Bioscientifica.com at 05/20/2019 02:40:22AM
via University of Adelaide -Internet
D M Rojas-Canales,  




microwell device over a distance of approximately 750 km 
(460 miles), with an average of 5.36 ± 0.51 h in transit 
(Supplementary Table  3) using a commercial courier. 
Islets were packaged according to the clinical guidelines 
for transportation (as described in the Materials and 
Methods section). Islets were shipped under temperature 
controlled conditions where shipments experienced stable 
temperature conditions (10–15°C, Supplementary Fig. 2B) 
throughout the transportation period. For comparison, 
islets were shipped in control tubes as part of the same 
consignment. Islets shipped in the microwell device had 
less PI-positive cell staining (Fig. 7D, E and F) compared to 
those control shipped (Fig. 7A, B and C), indicating better 
survival post transport. We also observed that islets shipped 
in the microwell device showed a trend toward improved 
OCRs (Fig. 7G) compared to tube control-shipped islets. 
Although this difference failed to reach significance 
(P = 0.067), four of five independent experiments showed 
increased OCR values for islets shipped in the microwell 
device, with improvements ranging from approximately 
19–58% compared to controls (Supplementary Fig.  2C). 
Moreover, when assessing islet mass, we found that 
microwell device shipped islets also retained a larger 
size during shipment (Fig. 7H). The average size of islets 
shipped in the microwell device was not significantly 
different from those cultured in normal conditions for the 
duration of the experiment.
These data suggest that the 500 µm microwell size is 
optimal for loading of human islets while preventing islet 
crowding in the wells. Additionally, the semi-permeable 
membrane positioned on top of the microwells restricted 
the movement of islets between wells. We found that 
Figure 6
Islet mRNA gene expression after pseudo-shipping. Islets were collected either directly after the 5-h pseudo-shipping period (white bars, n = 4 
independent experiments) or after a 24-h culture period (grey bars, n = 6 independent experiments). Islets cultured under standard culture conditions 
(culture control, black bars), exposed to 2% O2 (+hypoxia, n = 3, diagonal lines) or 100 ng/mL of TNF-alpha (TNF-alpha, n = 3, checkered) for 5 h were used 
as controls. RNA expression was analyzed by qRT-PCR for Ldha (A), Glut2 (Slc2a2) (B), Il6 (C), MCP1 (Ccl2) (D), insulin (Ins) (E) and Pdx1 (F), normalized to 
the housekeeping gene beta-actin. Results are shown as mean + S.d. of mRNA fold change from 5 h culture control. Statistics: One-way ANOVA, multiple 
comparisons, uncorrected Fisher’s LSD test where *P ≤ 0.05; ***P ≤ 0.001; ****P ≤ 0.0001.
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murine islets transported in the microwell device indeed 
showed improved viability according to FDA/PI staining 
and also a clear trend for improved OCR/DNA ratio, 
where 4 out of 5 shipments showed an improvement. 
Under both simulated and actual shipping conditions, 
the device demonstrated a significant maintenance of 
islet size, indicating that the physical separation provided 
by the microwell device has a positive effect on islet 
integrity. Currently, up to 40% of the islet mass can be lost 
during culture and transport and result in a preparation 
becoming unusable for infusion into the recipient (18, 
19). Therefore, maintenance of islet viability and integrity 
during the peri-transplant period is vital to ensure that a 
preparation is transplantable and is able to achieve the 
most favorable clinical outcome.
In conclusion, we have successfully generated a 
microwell device that supports the effective transport 
of islets, where segregation provided by the microwells 
prevented aggregation and fragmentation. We believe that 
the lack of aggregation observed in our microwell device 
helped maintain the expression of Ldha at basal levels in islets 
transported in the microwell device. More importantly, we 
have shown that improved transport conditions facilitated 
by our device can effectively limit the loss of islet mass and 
therefore potentially maintain the number of transplantable 
islets. The improvement of islet mass retention is critical in 
making this treatment more widely available, as currently 
some patients require up to six islet infusions to become 
insulin independent (68). Nonetheless, as the field moves 
from cadaver organs to other forms of stem cell and animal-
derived insulin-producing cell sources, this device has the 
capacity to provide superior transport conditions compared 
to the current state-of-the-art devices, in a relatively cost-
effective format.
Figure 7
Long-distance shipping of murine islets. Whole 
islet viability with FDA and PI was determined 
after shipping and an overnight culture period. 
Images shown include separated channels and 
overlay, control tube (control) (A, B and C) and 
islet shipped in microwell device (D, E and F), 
100× magnification. FDA/PI images are 
representative of 3 independent shipping 
experiments. Oxygen consumption rate 
normalized to DNA of the islets transported in 
the control tube and in the microwell device (G), 
and islet area measured from 100 islets selected 
randomly per condition (H). OCR and islet area 
imaging were performed 24 h post-shipping 
arrival at receiving center. (H) and (I) Show 
representative bright-field images taken at 40× 
magnification. (G) and (H) Show data from 5 
independent experiments mean+/− S.E.M., 
statistical analysis was completed with GraphPad 
Prism software. *P < 0.05, two-tailed T-test.
This work is licensed under a Creative Commons 
Attribution 4.0 International License.https://doi.org/10.1530/EC-17-0349
http://www.endocrineconnections.org © 2018 The authors
Published by Bioscientifica Ltd
Downloaded from Bioscientifica.com at 05/20/2019 02:40:22AM
via University of Adelaide -Internet
D M Rojas-Canales,  





This is linked to the online version of the paper at https://doi.org/10.1530/
EC-17-0349.
Declaration of interest
The authors declare that there is no conflict of interest that could be 
perceived as prejudicing the impartiality of the research reported.
Funding
This work was funded by the Cooperative Research Centre for Cell Therapy 
Manufacturing.
Acknowledgements
The authors thank Prof. Hans Griesser, Dr Thomas Michl and Marek 
Jasieniak for providing access to plasma reactor and protocol for the 
polymer coating. Christina Tan for her technical help and the islet isolation 
team at St Vincent’s Institute (supported by the Operational Infrastructure 
Support Scheme of the Government of Victoria). CCET is supported by 
grants from the Hospital Research Foundation and Kidney Transplant 
Diabetes Research Australia. The authors would like to acknowledge and 
thank Donate Life Australia and the donor families who provided consent 
for islets for human research. The whole team would like to thank the 
CRC-CTM for funding this research. Nicolas H Voelcker and Patrick T 
Coates: Senior authors.
References
 1 Federation I & Atlas ID. IDF Diabetes Atlas, 6th ed. Brussels, Belgium: 
International Diabetes Federation, 2013.
 2 Atkinson MA, Eisenbarth GS & Michels AW. Type 1 diabetes. Lancet 
2014 383 69–82. (https://doi.org/10.1016/S0140-6736(13)60591-7)
 3 Melmed S, Kleinberg D & Ho K. Pituitary Physiology and Diagnostic 
Evaluation. Williams Textbook of Endocrinology (Twelfth Edition), pp 
175–228. Philadelphia, PA, USA: Elsevier, 2012.
 4 Control D & Group CTR. The effect of intensive treatment of 
diabetes on the development and progression of long-term 
complications in insulin-dependent diabetes mellitus. New England 
Journal of Medicine 1993 1993 977–986.
 5 Bach J-F. Insulin-dependent diabetes mellitus as an autoimmune 
disease. Endocrine Reviews 1994 15 16–542. (https://doi.org/10.1210/
edrv-15-4-516)
 6 McDevitt H, Singer S & Tisch R. The role of MHC class II genes in 
susceptibility and resistance to type I diabetes mellitus in the NOD 
mouse. Hormone and Metabolic Research 1996 28 287–288. (https://
doi.org/10.1055/s-2007-979794)
 7 Haller MJ, Atkinson MA & Schatz D. Type 1 diabetes mellitus: 
etiology, presentation, and management. Pediatric Clinics of 
North America 2005 52 1553–1578. (https://doi.org/10.1016/j.
pcl.2005.07.006)
 8 Eisenbarth GS & Jeffrey J. The natural history of type 1A diabetes. 
Arquivos Brasileiros de Endocrinologia and Metabologia 2008 52 
146–155. (https://doi.org/10.1590/S0004-27302008000200002)
 9 Shapiro AJ, Ricordi C, Hering BJ, Auchincloss H, Lindblad R, 
Robertson RP, Secchi A, Brendel MD, Berney T & Brennan DC. 
International trial of the Edmonton protocol for islet 
transplantation. New England Journal of Medicine 2006 355  
1318–1330. (https://doi.org/10.1056/NEJMoa061267)
 10 Shapiro AJ, Lakey JR, Ryan EA, Korbutt GS, Toth E, Warnock GL, 
Kneteman NM & Rajotte RV. Islet transplantation in seven 
patients with type 1 diabetes mellitus using a glucocorticoid-free 
immunosuppressive regimen. New England Journal of Medicine 2000 
343 230–238. (https://doi.org/10.1056/NEJM200007273430401)
 11 Shapiro AJ. Strategies towards single-donor islets of Langerhans 
transplantation. Current Opinion in Organ Transplantation 2011 16 
627. (https://doi.org/10.1097/MOT.0b013e32834cfb84)
 12 Hering BJ, Clarke WR, Bridges ND, Eggerman TL, Alejandro R, 
Bellin MD, Chaloner K, Czarniecki CW, Goldstein JS, Hunsicker LG, 
et al. Phase 3 trial of transplantation of human islets in type 1 
diabetes complicated by severe hypoglycemia. Diabetes Care 2016 39 
1230–1240. (https://doi.org/10.2337/dc15-1988)
 13 Iwanaga Y, Sutherland DE, Harmon JV & Papas KK. Pancreas 
preservation for pancreas and islet transplantation. Current Opinion 
in Organ Transplantation 2008 13 445. (https://doi.org/10.1097/
MOT.0b013e328303df04)
 14 Hatziavramidis DT, Karatzas TM & Chrousos GP. Pancreatic islet cell 
transplantation: an update. Annals of Biomedical Engineering 2013 41 
469–476. (https://doi.org/10.1007/s10439-012-0676-3)
 15 Guignard AP, Oberholzer J, Benhamou P-Y, Touzet S, Bucher P, 
Penfornis A, Bayle F, Kessler L, Thivolet C & Badet L. Cost analysis 
of human islet transplantation for the treatment of type 1 diabetes 
in the Swiss-French Consortium GRAGIL. Diabetes Care 2004 27 
895–900. (https://doi.org/10.2337/diacare.27.4.895)
 16 Hengster P, Hermann M, Pirkebner D, Draxl A & Margreiter R. Islet 
isolation and GMP, ISO 9001: 2000: what do we need – a 3-year 
experience. Transplantation Proceedings 2005 37 3407–3408. (https://
doi.org/10.1016/j.transproceed.2005.09.075)
 17 O’Connell PJ, Holmes-Walker DJ, Goodman D, Hawthorne WJ, 
Loudovaris T, Gunton JE, Thomas HE, Grey ST, Drogemuller CJ, 
Ward GM, et al. Multicenter Australian trial of islet transplantation: 
improving accessibility and outcomes. American Journal of 
Transplantation 2013 13 1850–1858.
 18 Kin T, Senior P, O’Gorman D, Richer B, Salam A & Shapiro AMJ. 
Risk factors for islet loss during culture prior to transplantation. 
Transplant International 2008 21 1029–1035.
 19 Noguchi H, Naziruddin B, Jackson A, Shimoda M, Ikemoto T, 
Fujita Y, Chujo D, Takita M, Kobayashi N & Onaca N. Low-
temperature preservation of isolated islets is superior to conventional 
islet culture before islet transplantation. Transplantation 2010 89 
47–54. (https://doi.org/10.1097/TP.0b013e3181be3bf2)
 20 Kitzmann JP, Pepper AR, Gala-Lopez B, Pawlick R, Kin T, 
O’Gorman D, Mueller KR, Gruessner AC, Avgoustiniatos ES & 
Karatzas T. Human islet viability and function is maintained 
during high-density shipment in silicone rubber membrane vessels. 
Transplantation Proceedings 2014 46 1989–1991. (https://doi.
org/10.1016/j.transproceed.2014.06.002)
 21 Aldibbiat A, Huang GC, Zhao M, Holliman GN, Ferguson L, 
Hughes S, Brigham K, Wardle J, Williams R & Dickinson A. 
Validation of islet transport from a geographically distant isolation 
center enabling equitable access and National Health Service funding 
of a clinical islet transplant program for England. Cell Medicine 2012 
2 97–104. (https://doi.org/10.3727/215517911X617905)
 22 Ichii H, Sakuma Y, Pileggi A, Fraker C, Alvarez A, Montelongo J, 
Szust J, Khan A, Inverardi L & Naziruddin B. Shipment of human 
islets for transplantation. American Journal of Transplantation 2007 7 
1010–1020. (https://doi.org/10.1111/j.1600-6143.2006.01687.x)
 23 MacGregor R, Williams S, Tong P, Kover K, Moore W & Stehno-
Bittel L. Small rat islets are superior to large islets in in vitro function 
and in transplantation outcomes. American Journal of Physiology-
Endocrinology and Metabolism 2006 290 E771–E779. (https://doi.
org/10.1152/ajpendo.00097.2005)
 24 Lehmann R, Zuellig RA, Kugelmeier P, Baenninger PB, Moritz W, 
Perren A, Clavien P-A, Weber M & Spinas GA. Superiority of small 
islets in human islet transplantation. Diabetes 2007 56 594–603. 
(https://doi.org/10.2337/db06-0779)
 25 Fujita Y, Takita M, Shimoda M, Itoh T, Sugimoto K, Noguchi H, 
Naziruddin B, Levy MF & Matsumoto S. Large human islets secrete 
This work is licensed under a Creative Commons 
Attribution 4.0 International License.https://doi.org/10.1530/EC-17-0349
http://www.endocrineconnections.org © 2018 The authors
Published by Bioscientifica Ltd
Downloaded from Bioscientifica.com at 05/20/2019 02:40:22AM
via University of Adelaide -Internet
D M Rojas-Canales,  




less insulin per islet equivalent than smaller islets in vitro. Islets 2011 
3 1–5. (https://doi.org/10.4161/isl.3.1.14131)
 26 Avgoustiniatos ES, Hering BJ, Rozak PR, Wilson JR, Tempelman LA, 
Balamurugan AN, Welch DP, Weegman BP, Suszynski TM & Papas KK. 
Commercially available gas-permeable cell culture bags may 
not prevent anoxia in cultured or shipped islets. Transplantation 
Proceedings 2008 40 395–400. (https://doi.org/10.1016/j.
transproceed.2008.01.059)
 27 Griesser HJ. Small scale reactor for plasma processing of 
moving substrate web. Vacuum 1989 39 485–488. (https://doi.
org/10.1016/0042-207X(89)90272-8)
 28 Coad BR, Lu Y & Meagher L. A substrate-independent method 
for surface grafting polymer layers by atom transfer radical 
polymerization: reduction of protein adsorption. Acta 
Biomaterialia 2012 8 608–618. (https://doi.org/10.1016/j.
actbio.2011.10.006)
 29 McInnes SJ, Michl TD, Delalat B, Al-Bataineh SA, Coad BR, Vasilev K, 
Griesser HJ & Voelcker NH. “Thunderstruck”: plasma-polymer-coated 
porous silicon microparticles as a controlled drug delivery system. 
ACS Applied Materials and Interfaces 2016 8 4467–4476. (https://doi.
org/10.1021/acsami.5b12433)
 30 Graham KL, Fynch S, Papas EG, Tan C, Kay TW & Thomas HE. 
Isolation and culture of the islets of Langerhans from mouse 
pancreas. Bio-protocol 2016 6 e1840. (https://doi.org/10.21769/
BioProtoc.1840)
 31 Graham KL, Krishnamurthy B, Fynch S, Ayala‐Perez R, Slattery RM, 
Santamaria P, Thomas HE & Kay TW. Intra‐islet proliferation of 
cytotoxic T lymphocytes contributes to insulitis progression. 
European Journal of Immunology 2012 42 1717–1722. (https://doi.
org/10.1002/eji.201242435)
 32 Ricordi C, Lacy PE, Finke EH, Olack BJ & Scharp DW. Automated 
method for isolation of human pancreatic islets. Diabetes 1988 37 
413–420. (https://doi.org/10.2337/diab.37.4.413)
 33 Hermann M, Wurm M, Lubei V, Pirkebner D, Draxl A, Margreiter R 
& Hengster P. Keep on rolling: optimizing human islet transport 
conditions using a perfused rotary system. Islets 2012 4 152–157. 
(https://doi.org/10.4161/isl.19753)
 34 Oberhuber R, Mittermair C, Zelger B, Pirkebner D, Draxl A, 
Weissenbacher A, Resch T, Margreiter C, Sucher R & Margreiter R. 
Rotational transport of islets: the best way for islets to get around? 
BioMed Research International 2013 2013 7.
 35 Marathe CS, Drogemuller CJ, Marathe JA, Loudavaris T, 
Hawthorne WJ, O’Connell PJ, Radford T, Kay TW, Horowitz M, 
Coates PT, et al. Islet cell transplantation in Australia: screening, 
remote transplantation, and incretin hormone secretion in insulin 
independent patients. Hormone and Metabolic Research 2015 47 
16–23. (https://doi.org/10.1055/s-0034-1389941)
 36 Papas KK, Pisania A, Wu H, Weir GC & Colton CK. A stirred 
microchamber for oxygen consumption rate measurements with 
pancreatic islets. Biotechnology and Bioengineering 2007 98 1071–1082. 
(https://doi.org/10.1002/bit.21486)
 37 Forget A, Waibel M, Rojas-Canales DM, Chen S, Kawazoe N, 
Harding FJ, Loudovaris T, Coates PTH, Blencowe A, Chen G, et al. 
IGF-2 coated porous collagen microwells for the culture of pancreatic 
islets. Journal of Materials Chemistry B 2017 5 220–225. (https://doi.
org/10.1039/C6TB02748B)
 38 Dahlmann J, Kensah G, Kempf H, Skvorc D, Gawol A, Elliott DA, 
Drager G, Zweigerdt R, Martin U & Gruh I. The use of agarose 
microwells for scalable embryoid body formation and cardiac 
differentiation of human and murine pluripotent stem cells. 
Biomaterials 2013 34 2463–2471. (https://doi.org/10.1016/j.
biomaterials.2012.12.024)
 39 Liu T, Chien C-C, Parkinson L & Thierry B. Advanced 
micromachining of concave microwells for long term on-chip culture 
of multicellular tumor spheroids. ACS Applied Materials and Interfaces 
2014 6 8090–8097. (https://doi.org/10.1021/am500367h)
 40 Bernard AB, Lin C-C & Anseth KS. A microwell cell culture 
platform for the aggregation of pancreatic β-cells. Tissue Engineering 
Part C: Methods 2012 18 583–592. (https://doi.org/10.1089/ten.
tec.2011.0504)
 41 Buitinga M, Truckenmüller R, Engelse MA, Moroni L, Ten 
Hoopen HW, van Blitterswijk CA, de Koning EJ, van Apeldoorn AA & 
Karperien M. Microwell scaffolds for the extrahepatic transplantation 
of islets of Langerhans. PLoS ONE 2013 8 e64772. (https://doi.
org/10.1371/journal.pone.0064772)
 42 Forget A, Burzava ALS, Delalat B, Vasilev K, Harding FJ, 
Blencowe A & Voelcker NH. Rapid fabrication of functionalised 
poly(dimethylsiloxane) microwells for cell aggregate formation. 
Biomaterials Science 2017 5 828–836. (https://doi.org/10.1039/
C6BM00916F)
 43 Forget A, Staehly C, Ninan N, Harding FJ, Vasilev K, Voelcker NH 
& Blencowe A. Oxygen-releasing coatings for improved tissue 
preservation. ACS Biomaterials Science and Engineering 2017 3 
2384–2390. (https://doi.org/10.1021/acsbiomaterials.7b00297)
 44 Liu T, Winter M & Thierry B. Quasi-spherical microwells on 
superhydrophobic substrates for long term culture of multicellular 
spheroids and high throughput assays. Biomaterials 2014 35  
6060–6068. (https://doi.org/10.1016/j.biomaterials.2014.04.047)
 45 Rutter GA, Pullen TJ, Hodson DJ & Martinez-Sanchez A. Pancreatic 
beta-cell identity, glucose sensing and the control of insulin 
secretion. Biochemical Journal 2015 466 203–218. (https://doi.
org/10.1042/BJ20141384)
 46 Hilderink J, Spijker S, Carlotti F, Lange L, Engelse M, Blitterswijk C, 
Koning E, Karperien M & Apeldoorn A. Controlled aggregation of 
primary human pancreatic islet cells leads to glucose‐responsive 
pseudoislets comparable to native islets. Journal of Cellular and 
Molecular Medicine 2015 19 1836–1846. (https://doi.org/10.1111/
jcmm.12555)
 47 Jun Y, Kang AR, Lee JS, Park S-J, Lee DY, Moon S-H & Lee S-H. 
Microchip-based engineering of super-pancreatic islets supported by 
adipose-derived stem cells. Biomaterials 2014 35 4815–4826. (https://
doi.org/10.1016/j.biomaterials.2014.02.045)
 48 Hauge-Evans AC, Squires PE, Persaud SJ & Jones PM. Pancreatic beta-
cell-to-beta-cell interactions are required for integrated responses 
to nutrient stimuli: enhanced Ca2+ and insulin secretory responses 
of MIN6 pseudoislets. Diabetes 1999 48 1402–1408. (https://doi.
org/10.2337/diabetes.48.7.1402)
 49 Kramer D & Guilbault G. A substrate for the fluorometric 
determination of lipase activity. Analytical Chemistry 1963 35 
588–589. (https://doi.org/10.1021/ac60197a027)
 50 Shinohara M, Kimura H, Montagne K, Komori K, Fujii T & Sakai Y. 
Combination of microwell structures and direct oxygenation 
enables efficient and size‐regulated aggregate formation of an 
insulin‐secreting pancreatic β‐cell line. Biotechnology Progress 2014 30 
178–187. (https://doi.org/10.1002/btpr.1837)
 51 Ramírez-Domínguez M. Pancreatic islet isolation: from the mouse 
to the clinic. Advances in Experimental Medicine and Biology 2016. 
(https://doi.org/10.1007/978-3-319-39824-2)
 52 Kim T-S, Lee H-S, Oh S-H, Moon H, Lee S, Song S, Shin M, Park J, 
Kim S-J & Joh J-W. Optimal device and method for transportation of 
isolated porcine islet. Transplantation Proceedings 2013 45 3097–3101. 
(https://doi.org/10.1016/j.transproceed.2013.08.083)
 53 Barnett M, McGhee-Wilson D, Shapiro A & Lakey J. Variation 
in human islet viability based on different membrane integrity 
stains. Cell Transplantation 2004 13 481–488. (https://doi.
org/10.3727/000000004783983701)
 54 Boyd V, Cholewa OM & Papas KK. Limitations in the use of 
fluorescein diacetate/propidium iodide (FDA/PI) and cell permeable 
nucleic acid stains for viability measurements of isolated islets of 
Langerhans. Current Trends in Biotechnology and Pharmacy 2008 2 66.
 55 Papas KK, Colton C, Nelson R, Rozak P, Avgoustiniatos E, Scott W, 
Wildey G, Pisania A, Weir G & Hering B. Human islet oxygen 
This work is licensed under a Creative Commons 
Attribution 4.0 International License.https://doi.org/10.1530/EC-17-0349
http://www.endocrineconnections.org © 2018 The authors
Published by Bioscientifica Ltd
Downloaded from Bioscientifica.com at 05/20/2019 02:40:22AM
via University of Adelaide -Internet
D M Rojas-Canales,  




consumption rate and DNA measurements predict diabetes reversal 
in nude mice. American Journal of Transplantation 2007 7 707–713. 
(https://doi.org/10.1111/j.1600-6143.2006.01655.x)
 56 Cowley MJ, Weinberg A, Zammit NW, Walters SN, Hawthorne WJ, 
Loudovaris T, Thomas H, Kay T, Gunton JE & Alexander SI. Human 
islets express a marked proinflammatory molecular signature prior 
to transplantation. Cell Transplantation 2012 21 2063–2078. (https://
doi.org/10.3727/096368911X627372)
 57 Kitzmann J, O’Gorman D, Kin T, Gruessner AC, Senior P, Imes S, 
Gruessner R, Shapiro A & Papas KK. Islet oxygen consumption 
rate dose predicts insulin independence for first clinical islet 
allotransplants. Transplantation Proceedings 2014 46 1985–1988. 
(https://doi.org/10.1016/j.transproceed.2014.06.001)
 58 Cantley J, Walters SN, Jung M-H, Weinberg A, Cowley MJ, 
Whitworth P, Kaplan W, Hawthorne WJ, O’Connell PJ & Weir G. 
A preexistent hypoxic gene signature predicts impaired islet graft 
function and glucose homeostasis. Cell Transplantation 2013 22 
2147–2159. (https://doi.org/10.3727/096368912X658728)
 59 Marselli L, Thorne J, Ahn Y-B, Omer A, Sgroi DC, Libermann T, 
Otu HH, Sharma A, Bonner-Weir S & Weir GC. Gene expression 
of purified β-cell tissue obtained from human pancreas with laser 
capture microdissection. Journal of Clinical Endocrinology and 
Metabolism 2008 93 1046–1053. (https://doi.org/10.1210/jc.2007-
0931)
 60 Negi S, Jetha A, Aikin R, Hasilo C, Sladek R & Paraskevas S. Analysis 
of beta-cell gene expression reveals inflammatory signaling and 
evidence of dedifferentiation following human islet isolation and 
culture. PLoS ONE 2012 7 e30415. (https://doi.org/10.1371/journal.
pone.0030415)
 61 Stokes RA, Cheng K, Deters N, Lau SM, Hawthorne WJ, O’Connell PJ, 
Stolp J, Grey S, Loudovaris T & Kay TW. Hypoxia-inducible factor-1α  
(HIF-1α) potentiates β-cell survival after islet transplantation of 
human and mouse islets. Cell Transplantation 2013 22 253–266. 
(https://doi.org/10.3727/096368912X647180)
 62 Cantley J, Grey S, Maxwell P & Withers D. The hypoxia response 
pathway and β‐cell function. Diabetes, Obesity and Metabolism 2010 
12 159–167. (https://doi.org/10.1111/j.1463-1326.2010.01276.x)
 63 Kanak MA, Takita M, Kunnathodi F, Lawrence MC, Levy MF & 
Naziruddin B. Inflammatory response in islet transplantation. 
International Journal of Endocrinology 2014 2014 13.
 64 Zheng X, Wang X, Ma Z, Sunkari VG, Botusan I, Takeda T, 
Björklund A, Inoue M, Catrina S & Brismar K. Acute hypoxia induces 
apoptosis of pancreatic β-cell by activation of the unfolded protein 
response and upregulation of CHOP. Cell Death and Disease 2012 3 
e322. (https://doi.org/10.1038/cddis.2012.66)
 65 Pullen TJ, Khan AM, Barton G, Butcher SA, Sun G & Rutter GA. 
Identification of genes selectively disallowed in the pancreatic islet. 
Islets 2010 2 89–95. (https://doi.org/10.4161/isl.2.2.11025)
 66 Thorens B. GLUT2, glucose sensing and glucose homeostasis. 
Diabetologia 2015 58 221–232. (https://doi.org/10.1007/s00125-014-
3451-1)
 67 Thorens B, Wu YJ, Leahy JL & Weir GC. The loss of GLUT2 
expression by glucose-unresponsive beta cells of db/db mice is 
reversible and is induced by the diabetic environment. Journal 
of Clinical Investigation 1992 90 77–85. (https://doi.org/10.1172/
JCI115858)
 68 Balamurugan A, Naziruddin B, Lockridge A, Tiwari M, Loganathan G, 
Takita M, Matsumoto S, Papas K, Trieger M & Rainis H. Islet 
product characteristics and factors related to successful human islet 
transplantation from the Collaborative Islet Transplant Registry 
(CITR) 1999–2010. American Journal of Transplantation 2014 14 
2595–2606. (https://doi.org/10.1111/ajt.12872)
Received in final form 22 February 2018
Accepted 26 February 2018
Accepted Preprint published online 26 February 2018
This work is licensed under a Creative Commons 
Attribution 4.0 International License.https://doi.org/10.1530/EC-17-0349
http://www.endocrineconnections.org © 2018 The authors
Published by Bioscientifica Ltd
Downloaded from Bioscientifica.com at 05/20/2019 02:40:22AM
via University of Adelaide -Internet
